Le Lézard
Classified in: Health, Science and technology

Global Lactoferrin Market Drivers, Constraints, Threats Challenges & Opportunities During the Forecast Period, 2018-2027 - ResearchAndMarkets.com


The "Lactoferrin - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Lactoferrin Market accounted for $178.31 million in 2018 and is expected to reach $448.78 million by 2027 growing at a CAGR of 10.8% during the forecast period.

Rising geriatric population and several enhancements in medical science are the major factors driving the market growth. However, a cheap substitute in the form of generics is restraining market growth.

Lactoferrin is a multifunctional protein of the transferrin family. Lactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa that is widely represented in various secretory fluids, such as milk, saliva, tears, and nasal secretions. Lactoferrin is also present in secondary granules of PMNs and is secreted by some acinar cells. Lactoferrin can be purified from milk or produced recombinantly.

Based on the application, the sports & functional foods segment is likely to have a huge demand due to increasing participation and the awareness given for sports in addition, to the ageing population of the developed countries. By geography, Asia Pacific is going to have a lucrative growth during the forecast period due to growing awareness with a rising concern of maintaining their child health and increasing number of nuclear families in the region.

What the report offers:

Key Topics Covered:

1 Executive Summary

2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Application Analysis

3.7 Emerging Markets

3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Lactoferrin Market, By Application

5.1 Introduction

5.2 Infant Formula

5.3 Pharmaceuticals

5.4 Animal Feed

5.5 Food & Beverages

5.6 Sports & Functional Foods

5.7 Personal Care Products

6 Global Lactoferrin Market, By Function

6.1 Introduction

6.2 Anti-inflammatory

6.3 Antibacterial

6.4 Antioxidant

6.5 Iron Absorption

6.6 Intestinal Flora Protection

6.7 Immune Cell Stimulation

7 Global Lactoferrin Market, By Source

7.1 Introduction

7.2 Mammal Milk

7.3 Human Milk

8 Global Lactoferrin Market, By Form

8.1 Introduction

8.2 Iron-Free Apolactoferrin

8.3 Iron-Rich Hololactoferrin

9 Global Lactoferrin Market, By Geography

9.1 Introduction

9.2 North America

9.2.1 US

9.2.2 Canada

9.2.3 Mexico

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 Italy

9.3.4 France

9.3.5 Spain

9.3.6 Rest of Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 New Zealand

9.4.6 South Korea

9.4.7 Rest of Asia Pacific

9.5 South America

9.5.1 Argentina

9.5.2 Brazil

9.5.3 Chile

9.5.4 Rest of South America

9.6 Middle East & Africa

9.6.1 Saudi Arabia

9.6.2 UAE

9.6.3 Qatar

9.6.4 South Africa

9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures

10.2 Acquisitions & Mergers

10.3 New Product Launch

10.4 Expansions

10.5 Other Key Strategies

11 Company Profiling

11.1 Tatua Co-Operative Dairy Company Ltd

11.2 Synlait Milk Ltd

11.3 Royal FrieslandCampina

11.4 Merck KGaA

11.5 Ingredia SA

11.6 Glanbia PLC

11.7 Freedom Foods Group Ltd

11.8 Fonterra Co-operative Group Limited

11.9 Farbest Brands

11.10 Bega Cheese Limited

For more information about this report visit https://www.researchandmarkets.com/r/pl2ypb


These press releases may also interest you

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 07:00
R&D Leader and software architect with more than three decades of experience designing, developing,...

at 07:00
Gordian Biotechnology, an in vivo drug discovery and development...

at 07:00
GeBBS Healthcare Solutions, Inc.(ChrysCapital portfolio company) a leading provider of technology enabled Revenue Cycle Management (RCM) & Risk Adjustment Solutions for Healthcare Providers and Payers, announced the acquisition of CCD Health, a...

at 07:00
Many American children...



News published on and distributed by: